A report using the National cancer database of around twelve thousand advanced melanoma patients receiving immunotherapy with anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA4) and/or anti-PD1 treatment showed an apparent decrease in OS of younger patients under the age of 60 compared to elderly patients of above 60 years. The gene discussed is PDCD1; the disease is cancer.